Navigation Links
Study Reaffirms Superiority of Trofile(TM) Assay
Date:12/19/2007

ume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of s
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... 21, 2014 Telomere Biosciences, LLC (Telomere ... "TELO-20 for Dogs" with Telomerase Activation Complex ... the world for dogs. Telomeres are the protective ... the body. A wealth of ground-breaking research by ... Science and Aging, including Nobel laureates, has demonstrated ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Technologies, Inc., a leading,provider of innovative services ... today that Shabbir Anik, Ph.D.,will join the ... Officer. Dr.,Anik, the former President of Pharmaceutical ... Althea,s expansion of its product development,clinical trial ...
... advanced and powerful electron microscope on the planetcapable of ... for Electron Microscopy at McMaster University. , "We are ... of such a high calibre," says Gianluigi Botton, director ... Materials Science and Engineering, and the project,s leader. ...
... N.C., Oct. 20 With limited information ... support of Continuing,Medical Education activities, pharmaceutical, biotechnology ... understand the value of CME,support and strategies ... practitioner behaviors and patient outcomes. In the ...
Cached Biology Technology:Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer 2McMaster University unveils world's most advanced microscope 2Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME) 2
(Date:8/22/2014)... French . NAIROBI (22 ... soils looming as a major threat to food security across ... the last five years, 1.7 million African farmers in 13 ... hectares and helped them double or even triple crop yields. ... in Africa (AGRA) focuses on intensive efforts initiated five years ...
(Date:8/22/2014)... in basic and clinical research and technological advances, ... complex offensive spanning multiple fronts. , Work happening ... help find new and more selective therapies for ... a specific enzyme overexpressed in certain cancersand they ... tumours. , Chemistry professor Christopher Cairo and his ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... paleoclimate history by NASA,s Goddard Institute for Space Studies ... climate changes this century, including multiple meters of sea ... By looking at how the Earth,s climate responded to ... question raised by ongoing human-caused climate change: "What is ...
... Mellon University,s Roberto R. Gil and Rongchao Jin ... of infinitesimal gold nanoparticles, which could advance the ... drug development. Their approach offers a ... nanoparticles because it can determine whether the nanoparticles ...
... New York, NYDecember 7, 2011Thanks to a new ... be able to diagnose in their offices non-periodic ... Non-periodic arrhythmias include atrial and ventricular fibrillation, which ... can in some cases be life-threatening. ...
Cached Biology News:Paleoclimate record points toward potential rapid climate changes 2Paleoclimate record points toward potential rapid climate changes 3Paleoclimate record points toward potential rapid climate changes 4Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 2Carnegie Mellon researchers use NMR to determine whether gold nanoparticles exhibit 'handedness' 3New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2
... first instrument engineered to match the speed ... thousands of research centers worldwide. It uses ... are ideally suited for high-speed temperature cycling ... high surface-area-to-volume ratio. ,By combining glass capillary ...
... Antibody is a mouse monoclonal antibody ... 26 kDa glutathione-S-transferase (GST) domain from ... is suitable for detecting fusion proteins ... E. coli , yeast, mammalian, and ...
... at 470 nm; includes interface cable to S2000; ... into rack or desktop boxes The ... LED that produces either pulsed or continuous output ... for fluorescence measurements. The source is designed for ...
Sterile, Cell culture tested...
Biology Products: